Khorasanchi A, Hong F, Yang Y, Singer E, Wang P, Li M
Cancer Drug Resist. 2025; 8:9.
PMID: 40051495
PMC: 11883235.
DOI: 10.20517/cdr.2024.173.
Sipola J, Munzur A, Kwan E, Seo C, Hauk B, Parekh K
Cancer Res. 2024; 85(4):791-807.
PMID: 39652574
PMC: 11832346.
DOI: 10.1158/0008-5472.CAN-24-2052.
Zohourian N, Coll E, Dever M, Sheahan A, Burns-Lane P, Brown J
Cancers (Basel). 2024; 16(15).
PMID: 39123405
PMC: 11312108.
DOI: 10.3390/cancers16152677.
Parija M, Prakash S, Krishna B, Dash S, Mishra S
Breast Cancer. 2024; 31(3):440-455.
PMID: 38421553
DOI: 10.1007/s12282-024-01555-9.
Lumahan L, Arif M, Whitener A, Yi P
Cells. 2024; 13(2).
PMID: 38275816
PMC: 10814774.
DOI: 10.3390/cells13020191.
Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer.
Li X, Wang Y, Deng S, Zhu G, Wang C, Johnson N
Cancer Cell. 2023; 41(8):1427-1449.e12.
PMID: 37478850
PMC: 10530398.
DOI: 10.1016/j.ccell.2023.06.010.
The epigenetic function of androgen receptor in prostate cancer progression.
Sawada T, Kanemoto Y, Kurokawa T, Kato S
Front Cell Dev Biol. 2023; 11:1083486.
PMID: 37025180
PMC: 10070878.
DOI: 10.3389/fcell.2023.1083486.
FT-6876, a Potent and Selective Inhibitor of CBP/p300, is Active in Preclinical Models of Androgen Receptor-Positive Breast Cancer.
Caligiuri M, Williams G, Castro J, Battalagine L, Wilker E, Yao L
Target Oncol. 2023; 18(2):269-285.
PMID: 36826464
PMC: 10042772.
DOI: 10.1007/s11523-023-00949-7.
Acetyl-CoA Counteracts the Inhibitory Effect of Antiandrogens on Androgen Receptor Signaling in Prostate Cancer Cells.
Makhov P, Fazliyeva R, Tufano A, Uzzo R, Cai K, Serebriiskii I
Cancers (Basel). 2022; 14(23).
PMID: 36497382
PMC: 9738902.
DOI: 10.3390/cancers14235900.
Valeric acid acts as a novel HDAC3 inhibitor against prostate cancer.
Han R, Yang H, Li Y, Ling C, Lu L
Med Oncol. 2022; 39(12):213.
PMID: 36175803
PMC: 9522682.
DOI: 10.1007/s12032-022-01814-9.
Epigenetic Coregulation of Androgen Receptor Signaling.
Fernandes R, Leach D, Bevan C
Adv Exp Med Biol. 2022; 1390:277-293.
PMID: 36107325
DOI: 10.1007/978-3-031-11836-4_16.
Potential of histone deacetylase inhibitors in the control and regulation of prostate, breast and ovarian cancer.
Pramanik S, Halder A, Mukherjee U, Kumar D, Dey Y, R M
Front Chem. 2022; 10:948217.
PMID: 36034650
PMC: 9411967.
DOI: 10.3389/fchem.2022.948217.
Evidence that HDAC7 acts as an epigenetic "reader" of AR acetylation through NCoR-HDAC3 dissociation.
Zhang Y, Andrade R, Hanna A, Pflum M
Cell Chem Biol. 2022; 29(7):1162-1173.e5.
PMID: 35709754
PMC: 9450512.
DOI: 10.1016/j.chembiol.2022.05.008.
Roles of Key Epigenetic Regulators in the Gene Transcription and Progression of Prostate Cancer.
Deng T, Xiao Y, Dai Y, Xie L, Li X
Front Mol Biosci. 2022; 8:743376.
PMID: 34977151
PMC: 8714908.
DOI: 10.3389/fmolb.2021.743376.
KAT2A-mediated AR translocation into nucleus promotes abiraterone-resistance in castration-resistant prostate cancer.
Lu D, Song Y, Yu Y, Wang D, Liu B, Chen L
Cell Death Dis. 2021; 12(8):787.
PMID: 34381019
PMC: 8357915.
DOI: 10.1038/s41419-021-04077-w.
CBP/p300: Critical Co-Activators for Nuclear Steroid Hormone Receptors and Emerging Therapeutic Targets in Prostate and Breast Cancers.
Waddell A, Huang H, Liao D
Cancers (Basel). 2021; 13(12).
PMID: 34201346
PMC: 8229436.
DOI: 10.3390/cancers13122872.
Evaluating Mechanisms of IDH1 Regulation through Site-Specific Acetylation Mimics.
Weeks J, Strom A, Widjaja V, Alexander S, Pucher D, Sohl C
Biomolecules. 2021; 11(5).
PMID: 34065652
PMC: 8157008.
DOI: 10.3390/biom11050740.
Post-Translational Modifications That Drive Prostate Cancer Progression.
Samarzija I
Biomolecules. 2021; 11(2).
PMID: 33572160
PMC: 7915076.
DOI: 10.3390/biom11020247.
Targeting the p300/CBP Axis in Lethal Prostate Cancer.
Welti J, Sharp A, Brooks N, Yuan W, McNair C, Chand S
Cancer Discov. 2021; 11(5):1118-1137.
PMID: 33431496
PMC: 8102310.
DOI: 10.1158/2159-8290.CD-20-0751.
Isoform-specific Activities of Androgen Receptor and its Splice Variants in Prostate Cancer Cells.
Nagandla H, Robertson M, Putluri V, Putluri N, Coarfa C, Weigel N
Endocrinology. 2020; 162(3).
PMID: 33300995
PMC: 8253248.
DOI: 10.1210/endocr/bqaa227.